[Form 4] Sensient Technology Corporation Insider Trading Activity

Rhea-AI Filing Summary

On 30 June 2025, Sensient Technologies Corp. (SXT) director Dr. Joseph Carleone filed a Form 4 reporting the crediting of 370.737 deferred stock units under the company’s Directors’ Deferred Compensation Plan. These units convert to common stock on a one-for-one basis when his board service ends and carry no cash exercise price. After the accrual, Carleone’s direct beneficial ownership rises to 22,305.754 shares, up from 21,354.818 previously reported. No open-market purchase or sale occurred; the change stems solely from fee deferral. The transaction represents a <0.001% increase relative to SXT’s ~53 million shares outstanding and is therefore viewed as routine and immaterial to the company’s valuation or governance profile.

Insights

Financial Analyst

TL;DR: Routine, non-cash insider accrual; negligible impact on SXT valuation.

The filing shows a standard director fee deferral, adding only 371 shares to Dr. Carleone’s holdings. No open-market trade or cash transaction occurred, so it neither signals confidence nor concern. With the increase representing a fraction of a percent of the float, liquidity, earnings outlook and capital structure remain unaffected. I view the disclosure as neutral for investors.

Corporate Governance Expert

TL;DR: Indicates continued board alignment via equity, but quantitatively minor.

Deferred stock plans align director interests with shareholders over the long term. This filing confirms Dr. Carleone’s participation, reinforcing best-practice compensation design. However, the additional shares are small, and issuance is postponed until service termination, limiting any near-term governance or voting impact. Overall, it is procedural rather than strategic.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carleone Joseph

(Last) (First) (Middle)

777 EAST WISCONSIN AVENUE

(Street)

MILWAUKEE WI 53202

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SENSIENT TECHNOLOGIES CORP [ SXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								21,354.818(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock	(2)	06/30/2025		A(3)		370.737		(4)	(4)	Common Stock	370.737	$0	22,305.754	D

Explanation of Responses:

1. Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan.

2. Deferred stock converts to common stock on a one-for-one basis.

3. Deferral of director fees under Issuer's Directors' Deferred Compensation Plan.

4. Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer.

	/s/ John J. Manning, Attorney-in-Fact for Dr. Carleone	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Sensient Technologies (SXT) shares did Dr. Carleone acquire?

370.737 deferred stock units that convert 1-for-1 into common shares.

Was cash paid for the shares reported in the Form 4?

No. The units were credited in lieu of cash director fees at a $0 exercise price.

What is Dr. Carleone’s total beneficial ownership after the transaction?

He now directly owns 22,305.754 SXT common shares.

Does the filing indicate open-market buying or selling?

No. The increase stems from a deferred compensation plan, not a market trade.

When will the deferred stock convert to common stock?

Shares will be issued upon termination of Dr. Carleone’s board service.